Search Result

Results for "

20S

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Amyloid-β (2) Apoptosis (15) Autophagy (6) Bacterial (2) Caspase (2) COX (2) Cytochrome P450 (1) Deubiquitinase (1) Endogenous Metabolite (8) Estrogen Receptor/ERR (1) Glucocorticoid Receptor (1) IAP (1) LXR (1) Mitophagy (1) MMP (1) NF-κB (5) P-glycoprotein (1) Parasite (2) Potassium Channel (2) PROTAC Linkers (1) Proteasome (30) Reactive Oxygen Species (1) ROS Kinase (1) Smo (2) Sodium Channel (2) Survivin (1) Topoisomerase (4)
By Research Areas:	Cancer (36) Cardiovascular Disease (2) Endocrinology (1) Infection (3) Inflammation/Immunology (12) Metabolic Disease (1) Neurological Disease (6)

By Targets:

Akt (1)

Amyloid-β (2)

Apoptosis (15)

Autophagy (6)

Bacterial (2)

Caspase (2)

COX (2)

Cytochrome P450 (1)

Deubiquitinase (1)

Endogenous Metabolite (8)

Estrogen Receptor/ERR (1)

Glucocorticoid Receptor (1)

IAP (1)

LXR (1)

Mitophagy (1)

MMP (1)

NF-κB (5)

P-glycoprotein (1)

Parasite (2)

Potassium Channel (2)

PROTAC Linkers (1)

Proteasome (30)

Reactive Oxygen Species (1)

ROS Kinase (1)

Smo (2)

Sodium Channel (2)

Survivin (1)

Topoisomerase (4)

By Research Areas:

Cancer (36)

Cardiovascular Disease (2)

Endocrinology (1)

Infection (3)

Inflammation/Immunology (12)

Metabolic Disease (1)

Neurological Disease (6)

Inhibitors & Agonists

Fluorescent Dye

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-150602

20S Proteasome activator 1	Proteasome	Neurological Disease
20S Proteasome activator 1 is a potent 20S proteasome activator with EC₂₀₀ values of 0.3 μM, 0.7 μM and 1.8 μM for trypsin-like site, chymotrypsin-like site and caspase-like site. 20S Proteasome activator 1 translates well in a cellular system, preventing the accumulation of the pathogenic A53T mutant of α-synuclein. 20S Proteasome activator 1 can be used for researching neurodegenerative diseases .

HY-139331

20S Proteasome-IN-1	Proteasome	Neurological Disease Inflammation/Immunology Cancer
20S Proteasome-IN-1 is a 26S proteasome inhibitor extracted from patent WO2006128196A2 compound 2. 20S Proteasome-IN-1 has the potential for cancer, immune-related disorders, inflammation, ischemic conditions, neurodegenerative disorders and other diseases research .

HY-150591

20S Proteasome-IN-3

Proteasome Cancer

20S Proteasome-IN-3 is a 20S proteasome β5 subunit inhibitor (IC₅₀=1.64 μM) . 20S Proteasome-IN-3 shows anti-tumor proliferation activity .

20S Proteasome-IN-3	Proteasome	Cancer
20S Proteasome-IN-3 is a 20S proteasome β5 subunit inhibitor (IC₅₀=1.64 μM) . 20S Proteasome-IN-3 shows anti-tumor proliferation activity .

HY-151195

20S Proteasome-IN-4	Proteasome Parasite	Infection
20S Proteasome-IN-4 (Compound 7) is a brain-penetrant, parasite-selective, orally active 20S proteasome inhibitor with an IC₅₀ of 6.3 nM against T. b. brucei 20S proteasome. 20S Proteasome-IN-4 can be used for the research of human African trypanosomiasis (HAT) .

HY-150590

20S Proteasome-IN-2	Proteasome	Cancer
20S Proteasome-IN-2 is a human 20S proteasome inhibitor. 20S Proteasome-IN-2 shows high selectivity to its β5 subunit with the IC₅₀ of 0.18 μM. 20S Proteasome-IN-2 displays anti-proliferative effect in vitro and in vivo, and arrests cell cycle at G2/M .

HY-N0835

*(20S)-Protopanaxatriol* 20(S)-APPT; g-PPT	Glucocorticoid Receptor Estrogen Receptor/ERR LXR Apoptosis	Cardiovascular Disease Endocrinology
(20S)-Protopanaxatriol is a metabolite of ginsenoside. (20S)-Protopanaxatriol works through the glucocorticoid receptor (GR) and estrogen receptor (ER), and is also a LXRα inhibitor. (20S)-Protopanaxatriol shows a broad spectrum of antitumor effects .

HY-N12418

(20S)-18,19-Dehydrocamptothecin

Others Cancer

(20S)-18,19-Dehydrocamptothecin is a natural product that can be isolated from Nothapodytes Foetida .

*(20S)-18,19-Dehydrocamptothecin*	Others	Cancer
(20S)-18,19-Dehydrocamptothecin is a natural product that can be isolated from Nothapodytes Foetida .

HY-N0797

*(20S)-Protopanaxadiol* 20-Epiprotopanaxadiol; 20(S)-APPD	P-glycoprotein Reactive Oxygen Species Apoptosis	Cancer
20S-protopanaxadiol (aPPD) is a metabolite of ginseng saponins, inhibits Akt activity and induces apoptosis in various tumor cells .

HY-N10989

(20S)-Protopanaxadiol-3-one

Others Others

(20S)-Protopanaxadiol-3-one is a natural product found in Melia azedarach and Betula pendula .
HY-N6262

20(S),24(R)-Ocotillol

Others Others

20(S),24(R)-Ocotillol is isolated from Panax ginseng .

*(20S)-Protopanaxadiol-3-one*	Others	Others
(20S)-Protopanaxadiol-3-one is a natural product found in Melia azedarach and Betula pendula .

20(S),24(R)-Ocotillol	Others	Others
20(S),24(R)-Ocotillol is isolated from Panax ginseng .

HY-N0603R

20(S)-Ginsenoside Rg3 (Standard) 20(S)-Propanaxadiol(Standard); S-ginsenoside Rg3 (Standard)	Sodium Channel Potassium Channel NF-κB COX Amyloid-β Endogenous Metabolite	Neurological Disease Inflammation/Immunology Cancer
20(S)-Ginsenoside Rg3 (Standard) is the analytical standard of 20(S)-Ginsenoside Rg3. This product is intended for research and analytical applications. 20(S)-Ginsenoside Rg3 is the main component of Panax ginseng C. A. Meyer. Ginsenoside Rg3 inhibits Na ⁺ and hKv1.4 channel with IC₅₀s of 32.2±4.5 and 32.6±2.2 μM, respectively. 20(S)-Ginsenoside Rg3 also inhibits Aβ levels, NF-κB activity, and COX-2 expression.

HY-N1683

20(S),24(S)-Dihydroxydammar-25-en-3-one	Others	Others
20(S),24(S)-Dihydroxydammar-25-en-3-one (compound 19) is a kind of triterpene. 20(S),24(S)-Dihydroxydammar-25-en-3-one can be isolated from the floral spikes of Betula platyphylla var. 20(S),24(S)-Dihydroxydammar-25-en-3-one has cytotoxicity against Human Cancer Cell Lines .

HY-N0603

20(S)-Ginsenoside Rg3 4 Publications Verification 20(S)-Propanaxadiol; S-ginsenoside Rg3	Sodium Channel Potassium Channel NF-κB COX Amyloid-β Endogenous Metabolite	Neurological Disease Inflammation/Immunology Cancer
20(S)-Ginsenoside Rg3 is the main component of Panax ginseng C. A. Meyer. Ginsenoside Rg3 inhibits Na ⁺ and hKv1.4 channel with IC₅₀s of 32.2±4.5 and 32.6±2.2 μM, respectively. 20(S)-Ginsenoside Rg3 also inhibits Aβ levels, NF-κB activity, and COX-2 expression.

HY-12316R

20(S)-Hydroxycholesterol (Standard) 20α-Hydroxycholesterol (Standard)	Smo Endogenous Metabolite	Cancer
20(S)-Hydroxycholesterol (Standard) is the analytical standard of 20(S)-Hydroxycholesterol. This product is intended for research and analytical applications. 20(S)-hydroxyCholesterol (20α-Hydroxycholesterol) is an allosteric activator of the oncoprotein smoothened (Smo) that activates the hedgehog (Hh) signaling pathway with an EC₅₀ of 3 μM in a gene transcription reporter assay using NIH3T3 cells .

HY-12316

20(S)-Hydroxycholesterol 1 Publications Verification 20α-Hydroxycholesterol	Smo Endogenous Metabolite	Cancer
20(S)-hydroxyCholesterol (20α-Hydroxycholesterol) is an allosteric activator of the oncoprotein smoothened (Smo) that activates the hedgehog (Hh) signaling pathway with an EC₅₀ of 3 μM in a gene transcription reporter assay using NIH3T3 cells .

HY-N0605

Ginsenoside Rh2 3 Publications Verification 20(S)-Ginsenoside Rh2; 20(S)-Rh2; Ginsenoside-Rh2	Caspase Apoptosis Endogenous Metabolite	Cancer
Ginsenoside Rh2 induces the activation of caspase-8 and caspase-9. Ginsenoside Rh2 induces cancer cell apoptosis in a multi-path manner.

HY-N0605R

Ginsenoside Rh2 (Standard) 20(S)-Ginsenoside Rh2(Standard); 20(S)-Rh2(Standard); Ginsenoside-Rh2 (Standard)	Caspase Apoptosis Endogenous Metabolite	Cancer
Ginsenoside Rh2 (Standard) is the analytical standard of Ginsenoside Rh2. This product is intended for research and analytical applications. Ginsenoside Rh2 induces the activation of caspase-8 and caspase-9. Ginsenoside Rh2 induces cancer cell apoptosis in a multi-path manner.

HY-N0598

Ginsenoside F1 20(S)-Ginsenoside F1	Cytochrome P450 Endogenous Metabolite	Cancer
Ginsenoside F1, an enzymatically modified derivative of Ginsenoside Rg1, demonstrates competitive inhibition of CYP3A4 activity and weaker inhibition of CYP2D6 activity.

HY-N0909

Notoginsenoside R2 20(S)-Notoginsenoside R2; Ginsenoside Ng-R2	Apoptosis	Neurological Disease
Notoginsenoside R2 is a newly isolated notoginsenoside from Panax notoginseng, showed neuroprotective effects against 6-OHDA-induced oxidative stress and apoptosis.

HY-120722

TCH-165 1 Publications Verification	Proteasome	Cancer
TCH-165 is a small molecule modulator of proteasome assembly, which increases *20S* levels and facilitates *20S*-mediated protein degradation .

HY-129867

Z-Leu-Leu-Leu-AMC

Z-LLL-AMC
Proteasome Others

Z-Leu-Leu-Leu-AMC is a fluorogenic substrate for measuring the chymotrypsin-like protease activity of the 20S proteasome .
HY-123053

Z-Leu-Leu-Glu-AMC

Z-LLE-AMC
Proteasome Others

Z-Leu-Leu-Glu-AMC is a substrate peptide, and can be used for determination of postacidic-like hydrolysing activity of 20S proteasome
HY-123051

Ac-WLA-AMC

Proteasome Inflammation/Immunology

Ac-WLA-AMC is a specific 20S constitutive proteasome β5 fluorogenic substrate .

Z-Leu-Leu-Leu-AMC Z-LLL-AMC	Proteasome	Others
Z-Leu-Leu-Leu-AMC is a fluorogenic substrate for measuring the chymotrypsin-like protease activity of the 20S proteasome .

Z-Leu-Leu-Glu-AMC Z-LLE-AMC	Proteasome	Others
Z-Leu-Leu-Glu-AMC is a substrate peptide, and can be used for determination of postacidic-like hydrolysing activity of 20S proteasome

Ac-WLA-AMC	Proteasome	Inflammation/Immunology
Ac-WLA-AMC is a specific 20S constitutive proteasome β5 fluorogenic substrate .

HY-137286

Z-Leu-Leu-Glu-βNA Z-Leu-Leu-Glu-β-naphthylamide	Proteasome	Others
Z-Leu-Leu-Glu-βNA (Z-Leu-Leu-Glu-β-naphthylamide) is a substrate for determination of the glutamylpeptidyl-peptide hydrolase activity of the 20S proteasome .

HY-108552

MG-115 1 Publications Verification	Proteasome Apoptosis	Cancer
MG-115 is a potent and reversible proteasome inhibitor, with K_is of 21 nM and 35 nM for *20S* and 26S proteasome, respectively. MG-115 specifically inhibit the chymotrypsin-like activity of the proteasome, induces p53-dependent apoptosis .

HY-153034

LONP1-IN-2	Others	Cancer
LONP1-IN-2 (compound 9d) is a potent and selective LONP1 inhibitor with IC₅₀ values of 0.187 μM and >10 μM for LONP1 and 20S proteasome, respectively. LONP1-IN-2 can be used in research of cancer .

HY-W054146

RAMB4 1 Publications Verification	Proteasome	Cancer
RAMB4 is a ubiquitin-proteasome system (UPS)-stressor. RAMB4 inhibits ubiquitin-mediated protein degradation upstream of the 20S proteasomal catalytic activites. RAMB4 triggers a ubiquitin-proteasome-system (UPS)-stress response without affecting 20S proteasome catalytic activities. Anticancer activity .

HY-13067

Celastrol 30+ Cited Publications Tripterine; Tripterin	Proteasome Autophagy Mitophagy Apoptosis Endogenous Metabolite	Inflammation/Immunology Cancer
Celastrol (Tripterine;Tripterin) is a proteasome inhibitor which potently and preferentially inhibits the chymotrypsin-like activity of a purified 20S proteasome with IC₅₀ of 2.5 μM.

HY-10452

Ixazomib citrate 4 Publications Verification MLN9708	Proteasome Autophagy	Cancer
Ixazomib citrate (MLN9708) is a reversible inhibitor of the chymotrypsin-like proteolytic β5 site of the 20S proteasome with an IC₅₀ of 3.4 nM and a K_i of 0.93 nM.

HY-123052

Ac-PAL-AMC

Proteasome Inflammation/Immunology

Ac-PAL-AMC is a fluorogenic substrate specific for 20S proteasome LMP2/β1i activity .

Ac-PAL-AMC	Proteasome	Inflammation/Immunology
Ac-PAL-AMC is a fluorogenic substrate specific for 20S proteasome LMP2/β1i activity .

HY-107412

Proteasome inhibitor IX PS-IX; AM114	Proteasome	Cancer
Proteasome inhibitor IX (PS-IX; AM114) is a Chalcone derivative and a *chymotrypsin-like activity of the 20S* proteasome inhibitor with an IC₅₀ value of ~1 μM. Proteasome inhibitor IX exhibits HCT116 p53 ^+/+ cells growth inhibitory activity with an IC₅₀** value of 1.49 μM. Proteasome inhibitor IX has potent anticancer activity .

HY-10453

Ixazomib 10+ Cited Publications MLN2238	Proteasome Autophagy	Cancer
Ixazomib (MLN2238) is a selective, potent, and reversible proteasome inhibitor, which inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with an IC₅₀ of 3.4 nM (K_i of 0.93 nM).

HY-161032

IP6K2-IN-1

Others Inflammation/Immunology

IP6K2-IN-1 (Compd 20s) is a selective IP6K2 inhibitor, with an ICIC₅₀ value of 0.55?μM .

IP6K2-IN-1	Others	Inflammation/Immunology
IP6K2-IN-1 (Compd 20s) is a selective IP6K2 inhibitor, with an ICIC₅₀ value of 0.55?μM .

HY-N2117

Isoginkgetin 10+ Cited Publications	MMP Akt NF-κB Proteasome Apoptosis Autophagy	Inflammation/Immunology Cancer
Isoginkgetin is a pre-mRNA splicing inhibitor inhibitor. Isoginkgetin also inhibits activities of both Akt, NF-κB and MMP-9. Isoginkgetin inhibits the activity of the 20S proteasome, induces apoptosis and activates autophagy .

HY-150226

Enzyme-IN-1	Proteasome	Inflammation/Immunology
Enzyme-IN-1 (compound 1) is a peptide-based inhibitor of N-terminal nucleophile (Ntn) hydrolases. Specifically, Enzyme-IN-1 inhibits the chymotrypsin-like activity (CT-L) of the 20S proteasome. Enzyme-IN-1 may has potential antiinflammatory properties .

HY-N2166

Tomatine α-Tomatine; Lycopersicin; Tomatin
Tomatine is a glycoalkaloid, found in the tomato plant (Lycopersicon esculentum Mill.). Tomatine elicits neurotoxicity in RIP1 kinase and caspase-independent manner. Tomatine promotes the upregulation of nuclear apoptosis inducing factor (AIF) in neuroblastoma cells. Tomatine also inhibits 20S proteasome activity .

HY-113824

RID-F Ridaifen-F	Proteasome	Cancer
RID-F (Ridaifen-F), a Tamoxifen (HY-13757A) derivative, is a nonpeptidic proteasome inhibitor. RID-F inhibits human 20S proteasome activity, with IC₅₀s of 0.64, 0.34, and 0.43 μM for CT-L, T-L, and PGPH, respectively .

HY-149514

BC-05	Proteasome	Cancer
BC-05 is an orally active and potent inhibitor of CD13 and proteasome. BC-05 has an IC₅₀ value of 0.13 μM for human CD13 and an IC₅₀ value of 1.39 μM for the 20S proteasome. BC-05 can be used in multiple myeloma research .

HY-10227

Bortezomib Maximum Cited Publications 119 Publications Verification PS-341; LDP-341; NSC 681239	Proteasome NF-κB Apoptosis Autophagy	Cancer
Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (K_i=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Anti-cancer activity .

HY-108553

Dihydroeponemycin	Proteasome Apoptosis	Cancer
Dihydroeponemycin, an analogue of the antitumor and antiangiogenic natural product eponemycin, selectively targets the 20S proteasome. Dihydroeponemycin covalently modifies a subset of catalytic proteasomal subunits, binding preferentially to the IFN-gamma-inducible subunits LMP2 and LMP7. Dihydroeponemycin-mediated proteasome inhibition induces a spindle-like cellular morphological change and apoptosis .

HY-10985

Marizomib 5+ Cited Publications Salinosporamide A; NPI-0052	Proteasome	Cancer
Marizomib (Salinosporamide A) is a second-generation, irreversible, brain-penetrant, pan-proteasome inhibitor. Marizomib inhibits the CT-L (β5), CT-T-laspase-like (C-L, β1) and trypsin-like (T-L, β2) activities of the 20S proteasome (IC₅₀=3.5, 28, and 430 nM, respectively) .

HY-135396

(1S,2S)-Bortezomib	Proteasome Apoptosis	Cancer
(1S,2S)-Bortezomib is an enantiomer of Bortezomib. Bortezomib is a cell-permeable, reversible, and selective proteasome inhibitor, and potently inhibits 20S proteasome (K_i of 0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is an anti-cancer agent and the first therapeutic proteasome inhibitor to be used in humans .

HY-10227S

Bortezomib-d8 PS-341-d₈; LDP-341-d₈; NSC 681239-d₈	Proteasome NF-κB Apoptosis Autophagy	Cancer
Bortezomib-d₈ is the deuterium labeled Bortezomib. Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Anti-cancer activity[1][2].

HY-156407

Adam-20-S	Others	Others
Adam-20-S is a potent glucosinolate sulfatase inhibitor with an IC₅₀ value of 9.04 μg/mL. Adam-20-S impaires glucosinolate metabolism to produce more toxic isothiocyanates in P. xylostella .

HY-136528

RA-9	Deubiquitinase Apoptosis	Cancer
RA-9 is a potent and selective proteasome-associated deubiquitinating enzymes (DUBs) inhibitor with favorable toxicity profile and anticancer activity. RA-9 blocks ubiquitin-dependent protein degradation without impacting 20S proteasome proteolytic activity. RA-9 selectively induces onset of apoptosis in ovarian cancer cell lines and primary cultures derived from donors. RA-9 induces endoplasmic reticulum (ER)-stress responses in ovarian cancer cells .

HY-16594

Lactacystin 2 Publications Verification	Proteasome Apoptosis ROS Kinase	Infection Cardiovascular Disease Neurological Disease Cancer
Lactacystin is a potent, orally active, irreversible, cell-permeable, selective 20S proteasome inhibitor (IC₅₀ = 4.8 μM). Lactacystin also inhibits the lysosomal enzyme cathepsin A. Lactacystin inhibits cell growth and induces apoptosisand cell cycle arrest, and has antiviral and antioxidative activity. Lactacystin induces neurite outgrowth and hypertension. Lactacystin has the potential for the research of cancer, Neurological Disease, hypertension and Malaria, and so on ^[1] ^[2] ^[3] ^[4] ^[5] ^[6] ^[7] ^[8] ^[9] ^[10].

HY-114668

*Camptothecin-20(S)-O-propionate* Camptothecin-20-O-propionate	Topoisomerase	Cancer
Camptothecin-20(S)-O-propionate (CZ48), the C20-propionate ester of CPT, is a highly effective anticancer agent. Camptothecin-20(S)-O-propionate (CZ48) is a topoisomerase-Ι inhibitor .

HY-114668A

*Camptothecin-20(S)-O-propionate hydrate* Camptothecin-20-O-propionate hydrate	Topoisomerase	Cancer
Camptothecin-20(S)-O-propionate (Camptothecin-20-O-propionate) hydrate, the C20-propionate ester of CPT, is a highly effective anticancer agent. Camptothecin-20(S)-O-propionate hydrate is a topoisomerase-Ι inhibitor .

HY-157690A

19(R),20(S)-EDP

Others Others

19(R),20(S)-EDP (compound 19(S),20(R)-2a) is an oxylipin and a metabolite of docosahexaenoic acid (HY-B2167) .

HY-12486

FL118 10,11-(Methylenedioxy)-20(S)-camptothecin	Survivin Apoptosis IAP	Cancer
FL118 (10,11-(Methylenedioxy)-20(S)-camptothecin), a Camptothecin (HY-16560) analogue, is a potent and orally active survivin inhibitor. FL118 binds to oncoprotein DDX5 (p68) to dephosphorylates and degrades DDX5. FL118 can be used for the research of cancer .

Cat. No.	Product Name	Target	Research Area

HY-123053

Z-Leu-Leu-Glu-AMC

Z-LLE-AMC
Proteasome Others

Z-Leu-Leu-Glu-AMC is a substrate peptide, and can be used for determination of postacidic-like hydrolysing activity of 20S proteasome
HY-123051

Ac-WLA-AMC

Proteasome Inflammation/Immunology

Ac-WLA-AMC is a specific 20S constitutive proteasome β5 fluorogenic substrate .
HY-129867

Z-Leu-Leu-Leu-AMC

Z-LLL-AMC
Proteasome Others

Z-Leu-Leu-Leu-AMC is a fluorogenic substrate for measuring the chymotrypsin-like protease activity of the 20S proteasome .